+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sexually Transmitted Diseases Diagnostics Market by Disease Type (Chlamydia, Gonorrhea, Herpes Simplex Virus (HSV)), Test Types (Laboratory Testing, Point-of-Care Testing), Sample Type, End-User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sexually Transmitted Diseases Diagnostics Market by Disease Type (Chlamydia, Gonorrhea, Herpes Simplex Virus (HSV)), Test Types (Laboratory Testing, Point-of-Care Testing), Sample Type, End-User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Sexually Transmitted Diseases Diagnostics Market by Disease Type (Chlamydia, Gonorrhea, Herpes Simplex Virus (HSV)), Test Types (Laboratory Testing, Point-of-Care Testing), Sample Type, End-User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 182 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 6055581
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Sexually Transmitted Diseases Diagnostics Market grew from USD 12.78 billion in 2024 to USD 13.53 billion in 2025. It is expected to continue growing at a CAGR of 6.03%, reaching USD 18.17 billion by 2030.

In a landscape defined by rapid technological advancements and a deepening understanding of infectious diseases, sexually transmitted disease diagnostics have emerged as a critical frontier for both clinical and public health sectors. As global health challenges intensify, the need for early, precise, and accessible diagnostic solutions has never been greater. Advancements in molecular biology, biotechnology, and digital health have all converged to foster innovations that are both game changing and patient centered. This dynamic environment is not only reshaping the way healthcare providers detect and manage diseases but is also setting new benchmarks for regulatory bodies in terms of safety, efficacy, and quality assurance.

The evolution of diagnostic tools in this realm has been fueled by a convergence of clinical necessity, scientific breakthroughs, and market demands. Stakeholders ranging from research institutions and clinical laboratories to governmental agencies are collaborating to tackle the challenges that had long impeded early detection and effective intervention. As the global community strives to curb the incidence of sexually transmitted infections, the improved precision, speed, and accessibility of emerging diagnostic technologies promise better disease management and patient outcomes. This comprehensive overview offers not only a deep dive into ongoing shifts within the diagnostics industry but also lays the groundwork for a forward-looking strategy that encompasses the subtleties of market segmentation, regional peculiarities, and the roles played by leading players in this vital domain.

Transformative Shifts in the Diagnostics Landscape

The diagnostic landscape for sexually transmitted diseases has experienced transformative shifts, driven by a multitude of factors that collectively usher in a new era of clinical excellence. One of the most significant drivers is the integration of advanced molecular diagnostic techniques, which have drastically shortened detection times and increased the precision of test results. New technologies have paved the way for highly sensitive nucleic acid amplification methods that can detect infections even at the earliest stages, thereby enabling personalized and timely interventions.

Alongside these technological advancements comes the interplay of regulatory innovations that are ensuring a higher standard of care across hospitals, clinics, and even home-based settings. Enhanced regulatory frameworks have improved the validation processes for these diagnostic tools, instilling greater confidence among patients and providers alike. Moreover, evolving patient expectations have spurred a shift towards more accessible, accurate, and user-friendly platforms. These platforms, which range from sophisticated laboratory tests to point-of-care devices, are designed with the end-user in mind, ensuring that even those in the remotest areas have access to reliable diagnostics.

This transition is underscored by a growing emphasis on collaboration among biotech firms, healthcare providers, and governmental bodies. Collectively, these stakeholders are not only driving the pace of innovation but are also open to rethinking traditional approaches, thus ensuring that the marketplace remains fluid, responsive, and ahead of emerging health threats.

Key Segmentation Insights in STD Diagnostics

Deep insights drawn from market segmentation reveal a layered picture of the sexually transmitted diseases diagnostics arena. When considering disease type, the market is meticulously explored across conditions such as Chlamydia, Gonorrhea, Herpes Simplex Virus, Human Immunodeficiency Virus, Human Papillomavirus, and Syphilis. These conditions represent varied diagnostic challenges and dictate the need for specialized testing platforms capable of accurately identifying the breadth of curable and manageable infections.

Turning to the evolution of test modalities, the sector is broadly divided between Laboratory Testing and Point-of-Care Testing. Laboratory Testing is further enhanced by advanced technologies including Enzyme-linked Immunosorbent Assay, Nucleic Acid Amplification Tests, and Rapid Plasma Reagin, which collectively contribute to high throughput and precision analytics. Meanwhile, the rise of Point-of-Care Testing, exemplified by innovations such as Home Testing Kits and Rapid Tests, underscores a growing trend towards decentralization, where diagnostic results are increasingly obtained outside conventional laboratory environments.

Moreover, segmentation based on sample type - including blood, urine, and vaginal swabs - outlines the need for differential processing and optimized collection methods that are aligned with the biological characteristics of these samples. This technical diversity is compounded by the distinct end-user environments where the diagnostics are applied, spanning settings such as homecare, hospitals and clinics, point-of-care facilities, public health laboratories, and research laboratories. Finally, the way these diagnostic tools reach their intended markets is influenced by distribution strategies that navigate between direct sales and distributor channels. Each of these segmentation layers not only reinforces the complexity of the market but also highlights niche opportunities for tailored strategies that meet specific clinical and operational demands.

Based on Disease Type, market is studied across Chlamydia, Gonorrhea, Herpes Simplex Virus (HSV), Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), and Syphilis.

Based on Test Types, market is studied across Laboratory Testing and Point-of-Care Testing. The Laboratory Testing is further studied across Enzyme-linked Immunosorbent Assay (ELISA), Nucleic Acid Amplification Tests (NAATs), and Rapid Plasma Reagin (RPR). The Point-of-Care Testing is further studied across Home Testing Kits and Rapid Tests.

Based on Sample Type, market is studied across Blood, Urine, and Vaginal Swabs.

Based on End-User, market is studied across Homecare Settings, Hospitals & Clinics, Point-of-Care Settings, Public Health Labs, and Research Laboratories.

Based on Distribution Channel, market is studied across Direct Sales and Distributors.

Regional Insights Shaping the Global Market

Geographical insights underscore how regional dynamics have significantly contributed to the evolution of infectious disease diagnostics. In the Americas, robust healthcare infrastructures and well-established research initiatives have led to widespread adoption of innovative technologies, fostering an environment where clinical and point-of-care testing thrive in tandem. The region's proactive regulatory policies and investment in advanced diagnostic frameworks have also set a benchmark for other parts of the world.

Across Europe, the Middle East, and Africa, varying degrees of market maturity and infrastructure development have catalyzed a unique mix of conventional and state-of-the-art diagnostic approaches. While European markets often lean towards highly regulated laboratory-centric solutions, regions in the Middle East and Africa have witnessed a surge in adoption rates driven by urgent public health needs and a growing emphasis on improving accessibility. These regions are gradually shedding traditional dependence on centralized testing models, embracing mobile diagnostics and decentralized testing solutions that are tailored to local health challenges.

Meanwhile, the Asia-Pacific market stands out due to its diverse economic tapestry and rapid technological assimilation. Encouraged by rising investments in healthcare research and a burgeoning middle class, this region exhibits accelerated adoption of both laboratory-level innovations and point-of-care interventions. Together, these regional narratives highlight that while global trends serve as common threads, local conditions and regulatory frameworks play a paramount role in shaping the diagnostics landscape.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Driving Innovation in Diagnostics

The competitive arena in sexually transmitted disease diagnostics is marked by a blend of established giants and nimble innovators, each contributing distinct strengths that have elevated the industry. Notably, companies such as Abbott Laboratories, Astra Biotech GmbH, and Becton Dickinson and company continue to set industry benchmarks with comprehensive product portfolios and cutting-edge research initiatives. In addition, firms like Bio-Rad Laboratories, Inc. and bioMérieux SA play a pivotal role in advancing diagnostic accuracy through empirical research and technological refinement.

Industry leaders such as Danaher Corporation and F. Hoffmann-La Roche Ltd. are continually reimagining diagnostic paradigms by integrating digital health solutions with traditional testing methods, while Daye Limited and Diasorin S.p.A have shown marked prowess in deploying scalable and user-centric diagnostic tools. Moreover, emerging players including Geneproof, Hologic Inc., and Jiangsu BioPerfectus Technologies Co., Ltd have reinforced market competitiveness through their commitment to innovation and cost-effective solutions.

Other influential entities - Liferiver Bio-Tech Corp., MedMira Inc., Merck KGaA, Meridian Bioscience Inc., and Mylab Discovery Solutions Pvt. Ltd. - further illustrate the multifaceted approach needed to meet diverse clinical needs. Novartis AG, OraSure Technologies, Inc., Qiagen Inc., and Quest Consumer Inc. round out this robust lineup by driving innovations that span from molecular diagnostics to consumer-focused testing solutions. Dynamic participants like Sansure Biotech Inc., Seegene Inc., Siemens Healthineers AG, and Thermo Fisher Scientific, Inc. are collectively redefining benchmarks of quality and efficiency, ensuring that the industry remains at the forefront of diagnostic excellence.

The report delves into recent significant developments in the Sexually Transmitted Diseases Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astra Biotech GmbH, Becton Dickinson and company, Bio-Rad Laboratories, Inc., bioMérieux SA, Danaher Corporation, Daye Limited, Diasorin S.p.A, F. Hoffmann-La Roche Ltd., Geneproof, Hologic Inc., Jiangsu BioPerfectus Technologies Co., Ltd, Liferiver Bio-Tech Corp., MedMira Inc., Merck KGaA, Meridian Bioscience Inc., Mylab Discovery Solutions Pvt. Ltd., Novartis AG, OraSure Technologies, Inc., Qiagen Inc., Quest Consumer Inc., Sansure Biotech Inc., Seegene Inc., Siemens Healthineers AG, and Thermo Fisher Scientific, Inc..

Actionable Recommendations for Navigating Market Trends

For industry leaders looking to consolidate their foothold in the sexually transmitted disease diagnostics market, a strategic blend of innovation, investment, and foresight is essential. First, maintaining agility in research and development should be prioritized to continually adapt to evolving pathogen profiles and emergent diagnostic methodologies. This translates into investing in next-generation sequencing technologies and automation systems which help overcome the limitations of traditional testing approaches.

Second, companies must consider forging strategic collaborations with research institutions and technology innovators. Such partnerships can accelerate the integration of digital health platforms and data analytics, creating an ecosystem that is both predictive and responsive to epidemic trends. Furthermore, the convergence of traditional laboratory testing with point-of-care solutions is vital to cater to diverse customer needs.

Third, organizations are encouraged to adopt a customer-centric approach that leverages insights from market segmentation to tailor product offerings to specific user settings. Whether it is enhancing the sensitivity of tests based on sample types or optimizing distribution channels, every facet of product development should echo the nuances of local and global market demands. Lastly, continuous monitoring of regional regulatory frameworks is crucial to preemptively address compliance challenges and to seize competitive advantages in both established and emerging markets.

Paving the Way Forward in Diagnostics

In wrapping up this strategic analysis, the evolving sphere of sexually transmitted disease diagnostics not only embodies a critical confluence of scientific ingenuity and market imperatives but also highlights vast opportunities for growth and innovation. As the industry continues to pivot towards solutions that are both rapid and precise, the collective advancements in technology, collaboration, and market segmentation herald a new era of patient-centric care. Businesses that proactively harness these trends will find themselves well-equipped to tackle both current challenges and future uncertainties.

A balanced approach between embracing traditional laboratory excellence and fostering point-of-care ingenuity can prove to be a cornerstone for sustained success in this sector. By understanding the interplay of regional needs, demographic changes, and technological innovations, industry players can craft strategies that not only meet today’s requirements but also anticipate tomorrow’s evolutionary paths. Ultimately, building resilient frameworks and agile organizational cultures will be the key to unlocking the full potential of this vibrant market.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence and awareness of STDs globally
5.1.1.2. Growing implementation of supportive policies and initiatives from governments and health organizations
5.1.1.3. Expanded access to healthcare services facilitates greater availability and use of STD diagnostic services across globe
5.1.2. Restraints
5.1.2.1. Issues related to ability to keep diagnostic tests up-to-date with evolving strains and emerging pathogens
5.1.3. Opportunities
5.1.3.1. Growing potential with partnerships between diagnostic companies and healthcare providers or NGOs
5.1.3.2. Innovations in point-of-care testing to reduce the need for specialized laboratories and healthcare personnel
5.1.4. Challenges
5.1.4.1. Concerns associated with complex regulatory environments across different regions
5.2. Market Segmentation Analysis
5.2.1. Disease Type: Increasing need for nucleic acid amplification tests in chlamydia owing to high sensitivity and specificity
5.2.2. End-User: Proliferating applications of STD diagnostics in hospitals and clinics for accurate and timely diagnosis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Sexually Transmitted Diseases Diagnostics Market, by Disease Type
6.1. Introduction
6.2. Chlamydia
6.3. Gonorrhea
6.4. Herpes Simplex Virus (HSV)
6.5. Human Immunodeficiency Virus (HIV)
6.6. Human Papillomavirus (HPV)
6.7. Syphilis
7. Sexually Transmitted Diseases Diagnostics Market, by Test Types
7.1. Introduction
7.2. Laboratory Testing
7.2.1. Enzyme-linked Immunosorbent Assay (ELISA)
7.2.2. Nucleic Acid Amplification Tests (NAATs)
7.2.3. Rapid Plasma Reagin (RPR)
7.3. Point-of-Care Testing
7.3.1. Home Testing Kits
7.3.2. Rapid Tests
8. Sexually Transmitted Diseases Diagnostics Market, by Sample Type
8.1. Introduction
8.2. Blood
8.3. Urine
8.4. Vaginal Swabs
9. Sexually Transmitted Diseases Diagnostics Market, by End-User
9.1. Introduction
9.2. Homecare Settings
9.3. Hospitals & Clinics
9.4. Point-of-Care Settings
9.5. Public Health Labs
9.6. Research Laboratories
10. Sexually Transmitted Diseases Diagnostics Market, by Distribution Channel
10.1. Introduction
10.2. Direct Sales
10.3. Distributors
11. Americas Sexually Transmitted Diseases Diagnostics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Sexually Transmitted Diseases Diagnostics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Sexually Transmitted Diseases Diagnostics Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Scenario Analysis
14.3.1. Labcorp and NOWDiagnostics collaborate to expand rapid syphilis testing amid rising STI cases nationwide
14.3.2. Sherlock Biosciences innovative clinical trial for rapid OTC STI diagnostics
14.3.3. Binx Health secures USD 65 million to enhance rapid point-of-care STI diagnostics
14.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET MULTI-CURRENCY
FIGURE 2. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET MULTI-LANGUAGE
FIGURE 3. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 4. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 9. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2024 VS 2030 (%)
FIGURE 11. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 13. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 15. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 17. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 19. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 21. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 23. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 26. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 27. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET DYNAMICS
TABLE 7. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV), BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY RAPID PLASMA REAGIN (RPR), BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HOME TESTING KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY VAGINAL SWABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 60. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 61. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 62. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 63. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 64. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 67. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 68. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 69. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 70. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 71. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 82. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 83. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 84. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 89. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 90. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 91. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 92. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 93. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 94. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 97. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 98. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 99. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 100. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 101. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 104. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 105. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 106. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 107. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 108. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 111. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 112. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 113. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 114. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 115. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 116. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 118. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 119. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 120. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 121. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 122. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 125. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 126. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 127. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 128. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 129. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 132. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 133. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 134. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 135. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 136. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 139. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 140. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 141. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 142. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 143. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 146. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 147. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 148. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 149. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 150. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 153. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 154. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 155. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 156. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 157. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 160. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 161. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 162. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 163. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 164. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 165. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 167. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 168. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 169. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 170. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 171. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 172. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 181. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 182. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 183. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 184. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 185. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 186. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 187. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 189. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 190. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 191. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 192. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 193. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 196. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 197. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 198. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 199. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 200. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 201. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 203. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 204. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 205. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 206. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 207. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 208. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 210. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 211. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 212. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 213. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 214. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 215. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 217. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 218. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 219. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 220. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 221. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 222. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 224. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 225. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 226. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 227. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 228. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 231. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 232. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 245. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 246. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 247. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 248. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 249. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 250. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 252. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 253. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 254. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 255. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 256. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 257. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 259. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 260. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 261. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 262. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 263. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 264. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 266. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 270. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 271. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
TABLE 274. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
TABLE 276. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2

Companies Mentioned

  • Abbott Laboratories
  • Astra Biotech GmbH
  • Becton Dickinson and company
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Danaher Corporation
  • Daye Limited
  • Diasorin S.p.A
  • F. Hoffmann-La Roche Ltd.
  • Geneproof
  • Hologic Inc.
  • Jiangsu BioPerfectus Technologies Co., Ltd
  • Liferiver Bio-Tech Corp.
  • MedMira Inc.
  • Merck KGaA
  • Meridian Bioscience Inc.
  • Mylab Discovery Solutions Pvt. Ltd.
  • Novartis AG
  • OraSure Technologies, Inc.
  • Qiagen Inc.
  • Quest Consumer Inc.
  • Sansure Biotech Inc.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages182
PublishedMarch 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 13.53 Billion
Forecasted Market Value ( USD ) by 2030 $ 18.17 Billion
Compound Annual Growth Rate6.0%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Sexually Transmitted Disease Diagnostics Market by Disease Type, Diagnostic methods, Device Type, End-Users - Global Forecast 2025-2030 - Product Image

Sexually Transmitted Disease Diagnostics Market by Disease Type, Diagnostic methods, Device Type, End-Users - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Infectious Disease Diagnostic Market by Product, Technology, Testing Type, Sample, Application, End User - Global Forecast 2025-2030 - Product Image

Infectious Disease Diagnostic Market by Product, Technology, Testing Type, Sample, Application, End User - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Molecular Infectious Disease Testing Market by Product & Service (Kits, Instruments), Type (Singleplex, Multiplex), Test Type (Lab, PoC), Disease (STD, Flu, GI, HAI), Technology (PCR, NGS), End User (Diagnostic Labs, Hospitals) - Global Forecast to 2029 - Product Image

Molecular Infectious Disease Testing Market by Product & Service (Kits, Instruments), Type (Singleplex, Multiplex), Test Type (Lab, PoC), Disease (STD, Flu, GI, HAI), Technology (PCR, NGS), End User (Diagnostic Labs, Hospitals) - Global Forecast to 2029

  • Report
  • 449 Pages
  • Global
From
Sexually Transmitted Diseases Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Sexually Transmitted Diseases Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Sexually Transmitted Diseases (STDs) Drug - Global Strategic Business Report - Product Image

Sexually Transmitted Diseases (STDs) Drug - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.